Tiberio G A M, Ministrini S, Gardini A, Marrelli D, Marchet A, Cipollari C, Graziosi L, Pedrazzani C, Baiocchi G L, La Barba G, Roviello F, Donini A, de Manzoni G
Surgical Clinic, Department of Clinical and Experimental Sciences. University of Brescia, Italy.
Surgical Clinic, Department of Clinical and Experimental Sciences. University of Brescia, Italy.
Eur J Surg Oncol. 2016 Aug;42(8):1229-35. doi: 10.1016/j.ejso.2016.03.030. Epub 2016 Apr 19.
PURPOSE: To investigate clinical factors influencing the prognosis of patients submitted to hepatectomy for metastases from gastric cancer and their clinical role. METHODS: Retrospective multi-center chart review. We evaluated how survival from surgery was influenced by patient-related, gastric cancer-related, metastasis-related and treatment-related candidate prognostic factors. RESULTS: One hundred and five patients submitted to hepatectomy for metastases from gastric cancer, in the synchronous and metachronous setting of the disease. In 89 cases a R0 resection was achieved, while in 16 a R+ hepatic resection was performed. Adjuvant chemotherapy was administered to 29 patients. Surgical mortality was 1% and morbidity 13.3%. Median disease-free survival was 10 months, median overall survival was 14.6 months. Overall 1, 3, and 5-year survival rates were 58.2%, 20.3%, and 13.1%, respectively. Survival was influenced independently by the factor T of the gastric primary (p < 0.001), by the curativity of surgical procedure (p = 0.001), by the timing of hepatic involvement (p < 0.001) and by adjuvant chemotherapy (p < 0.001). T4 gastric cancer, R+ resection, synchronous metastases, and abstention from adjuvant chemotherapy were associated with a worse prognosis; T4 gastric cancer and R+ resections displayed a cumulative effect (p < 0.001). CONCLUSIONS: Our data show that R0 resection must be pursued whenever possible. Furthermore, in the synchronous setting, the coexistence of T4 gastric primaries and R+ resections suggests prudence and probably abstention from hepatectomy. Finally, a multimodal treatment associating surgery and chemotherapy offers the best survival results.
目的:探讨影响胃癌肝转移患者肝切除术后预后的临床因素及其临床作用。 方法:回顾性多中心病历审查。我们评估了患者相关、胃癌相关、转移相关和治疗相关的候选预后因素如何影响手术生存率。 结果:105例因胃癌肝转移接受肝切除术的患者,处于疾病的同步和异时状态。89例实现了R0切除,16例进行了R+肝切除。29例患者接受了辅助化疗。手术死亡率为1%,发病率为13.3%。无病生存期中位数为10个月,总生存期中位数为14.6个月。总体1年、3年和5年生存率分别为58.2%、20.3%和13.1%。生存独立受胃原发灶的T分期因素影响(p<0.001)、手术的根治性影响(p=0.001)、肝受累时间影响(p<0.001)以及辅助化疗影响(p<0.001)。T4期胃癌、R+切除、同步转移和未接受辅助化疗与较差的预后相关;T4期胃癌和R+切除显示出累积效应(p<0.001)。 结论:我们的数据表明,应尽可能争取R0切除。此外,在同步情况下,T4期胃原发灶与R+切除并存提示应谨慎行事,可能不宜进行肝切除。最后,手术与化疗相结合的多模式治疗可提供最佳生存结果。
Eur J Surg Oncol. 2016-8
Updates Surg. 2018-6
Eur J Surg Oncol. 2013-4-8
Eur J Surg Oncol. 2009-5
Curr Probl Cancer. 2017
Hepatogastroenterology. 2014
Zhonghua Wei Chang Wai Ke Za Zhi. 2005-1